Reference : Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK Gener...
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/29430
Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.
English
Breart, G. [> > > >]
Cooper, C. [> > > >]
Meyer, O. [> > > >]
Speirs, C. [> > > >]
Deltour, N. [> > > >]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
2010
Osteoporosis International
Springer Science & Business Media B.V.
21
1181-1195
Yes (verified by ORBi)
International
0937-941X
1433-2965
Godalming
United Kingdom
[en] In a retrospective cohort study using the General Practice Research Database (GPRD), there was a greater association of venous thromboembolism (VTE) in osteoporotic than in non-osteoporotic female patients. No greater association was shown in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic female patients. INTRODUCTION: We explored the risk of VTE in usual practice in osteoporotic and non-osteoporotic women with and without anti-osteoporotic treatment. METHODS: A retrospective study was conducted using the GPRD in the UK. The cohorts consisted of untreated osteoporotic women (N = 11,546), osteoporotic women treated with alendronate (N = 20,084), or strontium ranelate (N = 2,408), and a sample of non-osteoporotic women (N = 115,009). Cohorts were compared using a Cox proportional hazards regression model. RESULTS: There was a significantly increased relative risk for VTE in untreated osteoporotic women versus non-osteoporotic women (annual incidence 5.6 and 3.2 per 1,000 patient-years, respectively; relative risk 1.75 [95% confidence interval (CI), 1.09-1.84]). Results were confirmed using adjusted models. The annual incidences of VTE in osteoporotic patients treated with strontium ranelate and alendronate were 7.0 and 7.2 per 1,000 patient-years, respectively, with no significant difference between untreated and treated patients whatever the treatment. Adjusted hazard ratios for treated versus untreated osteoporotic women were 1.09 (95% CI, 0.60-2.01) for strontium ranelate and 0.92 (95% CI, 0.63-1.33) for alendronate. CONCLUSION: This study shows a greater association of VTE in osteoporotic compared to non-osteoporotic patients, but does not show any greater association in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic patients.
http://hdl.handle.net/2268/29430
10.1007/s00198-009-1050-7

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Osteoporosis and venous thromboembolism a retrospective cohort study in the UK General Practice.pdfPublisher postprint148.25 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.